{"id":"oral-anti-diabetics-oad","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lactic acidosis (metformin-associated)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OADs encompass multiple drug classes (sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 agonists, and others) that work through distinct pathways to reduce hyperglycemia. Sanofi manufactures several OAD products across these categories, each targeting different aspects of glucose homeostasis in type 2 diabetes management.","oneSentence":"Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:58:38.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06202079","phase":"PHASE2","title":"A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-08-11","conditions":"Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT06199505","phase":"PHASE2","title":"A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-11-21","conditions":"Type 2 Diabetes","enrollment":153},{"nctId":"NCT06145360","phase":"PHASE4","title":"Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient","status":"COMPLETED","sponsor":"SINA Health Education and Welfare Trust","startDate":"2023-12-01","conditions":"Glucose Metabolism Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents","enrollment":150},{"nctId":"NCT04227431","phase":"","title":"A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-17","conditions":"Diabetes Mellitus, Type 2","enrollment":938},{"nctId":"NCT05261867","phase":"","title":"Cardioprotective Effect of SGLT2-I in Diabetic Patients With AMI (SGLT2-I AMI PROTECT Study)","status":"UNKNOWN","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2017-01","conditions":"Diabetes Mellitus, Acute Coronary Syndrome","enrollment":800},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT03434119","phase":"PHASE3","title":"Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-02-20","conditions":"Type 2 Diabetes Mellitus","enrollment":241},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT03823339","phase":"","title":"A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-01-29","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT02607306","phase":"PHASE3","title":"A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-11-18","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":819},{"nctId":"NCT03015220","phase":"PHASE3","title":"Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":458},{"nctId":"NCT03687827","phase":"PHASE4","title":"A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":498},{"nctId":"NCT03175120","phase":"PHASE3","title":"A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-05-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":453},{"nctId":"NCT01650259","phase":"","title":"Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07-23","conditions":"Diabetes Mellitus, Type 2","enrollment":4876},{"nctId":"NCT03092752","phase":"","title":"Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":162116},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT01513590","phase":"PHASE3","title":"A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-16","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":394},{"nctId":"NCT01620489","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06-14","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":279},{"nctId":"NCT02004366","phase":"PHASE4","title":"Linagliptin Inpatient Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":295},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02606357","phase":"PHASE4","title":"Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-22","conditions":"Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT02219750","phase":"PHASE4","title":"Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2013-08","conditions":"Diabetes","enrollment":181},{"nctId":"NCT01512108","phase":"PHASE3","title":"Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":363},{"nctId":"NCT01814137","phase":"PHASE3","title":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT01364428","phase":"PHASE3","title":"Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":373},{"nctId":"NCT01238978","phase":"PHASE4","title":"Phase 4 Study in the Elderly Patients With T2DM","status":"COMPLETED","sponsor":"Novartis","startDate":"2010-10","conditions":"Type 2 Diabetes Mellitus, Elderly","enrollment":46},{"nctId":"NCT00982644","phase":"PHASE3","title":"Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1030},{"nctId":"NCT00700960","phase":"","title":"Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":2745},{"nctId":"NCT00842192","phase":"","title":"An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":2155},{"nctId":"NCT00665808","phase":"","title":"Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During \"Real-life\" Usage in Germany","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":8125},{"nctId":"NCT01377935","phase":"","title":"Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Diabetes Mellitus, Type 2","enrollment":113505},{"nctId":"NCT01135992","phase":"PHASE3","title":"Switching From Insulin Glargine to Insulin Degludec in Subjects With Type 2 Diabetes Mellitus (BEGIN™)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":143},{"nctId":"NCT01326598","phase":"","title":"Effectiveness of V-Go™ for Patients With Diabetes in a Real-world Setting","status":"COMPLETED","sponsor":"Valeritas, Inc.","startDate":"2012-01","conditions":"Type 2 Diabetes Mellitus","enrollment":270},{"nctId":"NCT00506194","phase":"NA","title":"Short-Term Intensive Insulin Therapy Induction of Long-term Glycemic Control","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT00978263","phase":"NA","title":"Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2009-02","conditions":"Diabetes","enrollment":47},{"nctId":"NCT00965549","phase":"PHASE4","title":"Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":463},{"nctId":"NCT00949442","phase":"PHASE4","title":"Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":708},{"nctId":"NCT00908921","phase":"PHASE4","title":"Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Diabetes Mellitus, Type 2","enrollment":391},{"nctId":"NCT01275794","phase":"","title":"Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-12","conditions":"Type 2 Diabetes","enrollment":1849},{"nctId":"NCT00950534","phase":"PHASE4","title":"Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT00272012","phase":"PHASE3","title":"OPAL - Insulin Glulisine, Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-07","conditions":"Diabetes Mellitus Type 2","enrollment":396},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":394,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Oral Anti Diabetics (OAD)","genericName":"Oral Anti Diabetics (OAD)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral anti-diabetics are a class of medications that lower blood glucose through various mechanisms including insulin secretion stimulation, insulin sensitivity improvement, or glucose absorption reduction. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}